Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia

← catalyst calendar

NCT05891847

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

—

Status

Terminated

Study type

Observational

Enrollment

150actual

Sites

Country

Russia

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Statistically significant failure to achieve key secondary endpoints. The current data do not demonstrate sufficient potential to achieve the planned scientific objectives. The need to optimize the allocation of company resources.

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-03-21

actual

When the study began enrolling

Primary completion

2025-07-11

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-07-11

actual

The whole study's end, after follow-up

First posted

2023-06-07

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-08

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Neurofibroma